Biobeat Secures $50 Million Series B Financing to Advance Commercialization of its Patch-worn, Cuff-less 24-hour Ambulatory Blood Pressure Monitor
Biobeat Technologies, Ltd., developer of the first FDA-cleared, 24-hour ambulatory blood pressure monitoring (ABPM) system that is a patch-worn, cuff-less solution for diagnosis and treatment of hypertension, announced today the closing of a $50 million Series B equity financing.
